uniQure (NASDAQ:QURE) Stock Price Up 4.7% - Still a Buy?

Shares of uniQure (NASDAQ:QURE - Get Free Report) were up 4.7% on Wednesday . The company traded as high as $10.23 and last traded at $10.38. Approximately 137,645 shares were traded during trading, a decline of 92% from the average daily volume of 1,650,801 shares. The stock had previously closed at $9.91.

Wall Street Analyst Weigh In

Several research firms have commented on QURE. Guggenheim reissued a "buy" rating on shares of uniQure in a research report on Wednesday, December 11th. StockNews.com raised uniQure to a "sell" rating in a report on Tuesday, March 11th. Leerink Partners boosted their price target on shares of uniQure from $26.00 to $44.00 and gave the stock an "outperform" rating in a research note on Wednesday, December 11th. Mizuho upped their price target on shares of uniQure from $7.00 to $20.00 and gave the company a "neutral" rating in a report on Thursday, December 19th. Finally, Stifel Nicolaus lifted their target price on uniQure from $12.00 to $32.00 and gave the company a "buy" rating in a research report on Monday, December 16th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $38.80.

uniQure Price Performance

The business's fifty day simple moving average is $13.25 and its 200-day simple moving average is $10.98. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92. The firm has a market cap of $464.31 million, a P/E ratio of -1.73 and a beta of 0.42.

Insider Transactions at uniQure

In related news, CFO Christian Klemt sold 14,341 shares of the business's stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $10.70, for a total transaction of $153,448.70. Following the sale, the chief financial officer now owns 152,372 shares of the company's stock, valued at $1,630,380.40. The trade was a 8.60 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Matthew C. Kapusta sold 6,717 shares of the business's stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $11.32, for a total value of $76,036.44. Following the completion of the transaction, the chief executive officer now owns 580,795 shares of the company's stock, valued at $6,574,599.40. This represents a 1.14 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 90,830 shares of company stock worth $961,401. 4.74% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Avoro Capital Advisors LLC bought a new position in shares of uniQure in the 4th quarter worth $38,410,000. Franklin Resources Inc. boosted its stake in uniQure by 33.1% during the fourth quarter. Franklin Resources Inc. now owns 1,987,688 shares of the biotechnology company's stock worth $35,103,000 after buying an additional 494,726 shares during the last quarter. Point72 Asset Management L.P. grew its holdings in shares of uniQure by 81.3% during the 4th quarter. Point72 Asset Management L.P. now owns 1,771,352 shares of the biotechnology company's stock worth $31,282,000 after purchasing an additional 794,459 shares during the period. Integral Health Asset Management LLC raised its holdings in shares of uniQure by 175.0% in the 4th quarter. Integral Health Asset Management LLC now owns 1,100,000 shares of the biotechnology company's stock valued at $19,426,000 after buying an additional 700,000 shares during the period. Finally, RTW Investments LP increased its position in shares of uniQure by 8,936.3% during the fourth quarter. RTW Investments LP now owns 903,625 shares of the biotechnology company's stock worth $15,958,000 after acquiring an additional 893,625 shares during the period. Institutional investors own 78.83% of the company's stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.